• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    USANA Health Sciences Reports Fourth Quarter and Full Year 2024 Results and Provides Fiscal Year 2025 Outlook

    2/25/25 4:10:00 PM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $USNA alert in real time by email

    USANA Health Sciences, Inc. (NYSE:USNA) (the "Company") today announced financial results for its fiscal fourth quarter and fiscal year ended December 28, 2024. The Company completed the acquisition of a 78.8% controlling ownership stake of Hiya Health Products, LLC ("Hiya") on December 23, 2024. Consequently, the Company's fourth quarter and fiscal year 2024 include the effect of less than a week of Hiya's operating results, which were not significant to the Company's consolidated results for the same periods. In light of the Hiya acquisition, the Company is now including metrics for Adjusted diluted EPS(1) and Adjusted EBITDA(2). Net earnings, Diluted EPS, Adjusted diluted EPS(1) and Adjusted EBITDA(2) in this press release represent amounts attributable to USANA.

    Key Financial Results and Guidance

    Fourth Quarter 2024 vs. Fourth Quarter 2023

    • Net sales of $214 million versus $221 million.
    • Net earnings of $4.5 million as compared to $16.8 million.
    • Diluted EPS of $0.23 as compared with $0.87.
    • Adjusted diluted EPS(1) of $0.64 as compared with $0.87.
    • Adjusted EBITDA(2) of $25 million versus $32 million.
    • USANA Active Customers of 454,000 versus 483,000.

    Fiscal Year 2024 vs. Fiscal Year 2023

    • Net sales of $855 million as compared with $921 million.
    • Net earnings of $42.0 million as compared to $63.8 million.
    • Diluted EPS of $2.19 versus $3.30.
    • Adjusted diluted EPS(1) of $2.59 as compared with $3.30.
    • Adjusted EBITDA(2) of $110 million versus $128 million.

    Fiscal Year 2025 Outlook

    • Consolidated net sales between $920 million and $1.0 billion, or 8% - 17% growth.
    • Net earnings between $29 million and $41 million.
    • Diluted EPS between $1.50 and $2.20.
    • Adjusted Diluted EPS(1) between $2.35 and $3.00.
    • Adjusted EBITDA(2) between $107 million and $123 million.

    Q4 2024 Financial Performance

    Consolidated Results

    (Net earnings, EPS and EBITDA figures represent

    amounts attributable to USANA)

    Year-over-Year

    Sequentially

    Net Sales

    $214 million

    -3% (No meaningful FX impact)

    +7%

    Net Earnings

    $4.5 million

    -73%

    -58%

    Diluted EPS

    $0.23

    -74%

    -59%

    Adjusted Diluted EPS(1)

    $0.64

    -26%

    +14%

    Adjusted EBITDA(2)

    $25 million

    -21%

    +4%

    "USANA delivered fourth quarter results above our internal expectations, highlighted by 7% sequential net sales growth," said Jim Brown, President and Chief Executive Officer. "Positive momentum in the Americas & Europe region generated year-over-year and sequential sales growth in this region while performance in our Asia Pacific region declined slightly and was in line with our expectations. On a consolidated basis, we generated solid cash flow during the quarter and our balance sheet remains in a healthy net cash position. Overall, we delivered solid performance to finish the year and are confident in our ability to build on this performance in 2025."

    Mr. Brown added, "We also completed our acquisition of Hiya during the quarter, which is a meaningful milestone for USANA and an exciting addition to our business. Hiya is a growing, highly cash generative, direct-to-consumer children's wellness brand. Hiya has an experienced management team that continues to lead the company and a compelling subscription business model that we believe is positioned to deliver long-term sustainable growth over the next several years. We look forward to supporting Hiya as they build upon their leadership position in the children's health and wellness market."

    Fiscal Year 2024 vs. Fiscal Year 2023 Financial Performance

    Consolidated Results

    Net Sales

    $855 million

    -7% YOY

     

     

    -6% constant currency

     

     

    -$14 million YOY FX impact

    Net Earnings

    $42.0 million

    -34%

    Diluted EPS

    $2.19

    -34%

    Adjusted Diluted EPS(1)

    $2.59

    -21%

    Adjusted EBITDA(2)

    $110 million

    -14%

    Net earnings, EPS and EBITDA figures represent amounts attributable to USANA

    Mr. Brown continued, "Full year operating results reflected continued, cautious consumer sentiment in many of our key Asia Pacific markets. This made it difficult to attract new customers and generate positive momentum throughout the year. Notwithstanding these factors, our commercial team made progress on several meaningful initiatives which will begin rolling out across our direct sales business this year. We are confident that these initiatives will lay the foundation for the Company to generate long term growth."

    Q4 2024 Regional Results:

    Asia Pacific Region

     

    Year-

    Over-Year

    Year-over-Year

    (Constant Currency)

    Sequentially

    Net Sales

    $167 million

    -6%

    No material FX impact

    +4%

    USANA Active Customers

    361,000

    -6%

    n.a.

    Flat

    Asia Pacific Sub-Regions

     

    Year-

    Over-Year

    Year-over-Year

    (Constant Currency)

    Sequentially

    Greater China

    Net Sales

    $113 million

    -3%

    No material FX impact

    +10%

    USANA Active

    246,000

    -4%

    n.a.

    +1%

    Customers

    North Asia

    Net Sales

    $17 million

    -25%

    -21%

    -19%

    USANA Active

    38,000

    -21%

    n.a.

    -7%

    Customers

    Southeast Asia Pacific

    Net Sales

    $38 million

    -3%

    -4%

    +2%

    USANA Active

    77,000

    -4%

    n.a.

    +1%

    Customers

    Americas and Europe Region

     

    Year-

    Over-Year

    Year-over-Year

    (Constant Currency)

    Sequentially

    Net Sales

    $44 million

    +1%

    +3%

    +11%

    USANA Active Customers

    93,000

    -7%

    n.a.

    +1%

    Hiya contributed approximately $2 million to net sales during the fourth quarter and fiscal year ended 2024.

    Balance Sheet and Share Repurchase Activity

    During the fourth quarter, the Company continued to generate strong operating cash flow and invested approximately $206 million for the acquisition of Hiya. Consequently, the Company ended the year with $182 million in cash and cash equivalents. The Company did not repurchase any shares during the quarter. As of December 28, 2024, the Company had approximately $62 million remaining under the current share repurchase authorization.

    Fiscal Year 2025 Outlook

    Mr. Brown continued, "Our growth strategy for the direct sales business in 2025 is centered on our Associate sales force and providing them with the resources needed to generate sustainable active customer growth. This growth strategy includes several key initiatives, including (i) a higher cadence of new product launches and improvements to existing products tailored to local markets, (ii) strategic enhancements and modifications to our Associate incentive offering, which are intended to incent customer growth and improve pay for performance, (iii) strengthening our brand messaging, story, and value proposition, and (iv) accelerating Associate engagement activities in our regions around the world. I'm confident that the successful execution of these initiatives will position us for growth going forward.

    "Hiya's strategic priorities for this year include capitalizing on recent product launches to drive further growth in its direct-to-consumer model, expanding strategic partnerships, and laying the groundwork for channel expansion. We are also working closely with the Hiya team to identify both short- and long-term synergy opportunities. Overall, we remain confident that the Hiya team, which continues to be led by co-founders Darren Litt and Adam Gillman, will deliver strong growth in 2025."

    The Company is providing its outlook for fiscal year 2025, as detailed in the table below:

     

    Twelve Months Ended

    January 3, 2026

     

    Range

    Consolidated net sales

    $920 million to $1.0 billion

    Net Earnings

    $29 million to $41 million

    Diluted EPS

    $1.50 to $2.20

    Adjusted diluted EPS(1)

    $2.35 to $3.00

    Adjusted EBITDA(2)

    $107 million to $123 million

    Doug Hekking, Chief Financial Officer, said, "We are introducing our consolidated fiscal 2025 outlook, which now includes additional non-GAAP financial metrics to help provide transparency and comparability with prior years following our acquisition of Hiya. Notably, we have included certain transaction-related expenses and integration costs for the Hiya acquisition in our outlook. Furthermore, the purchase price allocation for this acquisition includes a significant amount recognized as intangible assets with material amortization expense that will have a non-cash impact on reported results. Therefore, we are providing estimates for Adjusted diluted EPS(1) and Adjusted EBITDA(2) as part of our outlook to provide enhanced comparability between periods and improved clarity on cash flow generation of the combined enterprise on a year-over-year basis. Additionally, our outlook does not currently reflect the potential increased costs of proposed tariffs on our business as we continue to assess the changing business environment."

    The Company's outlook reflects:

    • Net sales from the USANA business of $775 to $840 million, which includes an expected unfavorable currency exchange rate impact of approximately $30 million, or -4% on net sales;
    • Net sales from Hiya of $145 to $160 million, reflecting a year-over-year range of +29% to +42%;
    • Effective tax rate of 41.5% to 45.0%;
    • Annualized diluted share count of 19.1 million; and
    • Fiscal 2025 is a 53-week year and includes one additional week of sales compared to fiscal 2024. Prior to 2025, the last 53-week year was in fiscal 2020.

    _________________________

    (1) Adjusted Diluted Earnings Per Share is a non-GAAP financial measure. The Company excludes acquisition-related costs, such as business transaction costs, integration expense and amortization expense from acquisition related intangible assets in calculating Adjusted Diluted Earnings Per Share. Please refer to "Non-GAAP Financial Measures" and "Reconciliation of Diluted Earnings Per Share (GAAP) to Adjusted Diluted Earnings Per Share (Non-GAAP)" in this press release for an explanation and reconciliation of this non-GAAP financial measure.

    (2) Adjusted EBITDA is a non-GAAP financial measure. Please refer to "Non-GAAP Financial Measures" and "Reconciliation of Net Earnings (GAAP) to Adjusted EBITDA (Non-GAAP)" in this press release for an explanation and reconciliation of this non-GAAP financial measure.

    Non-GAAP Financial Measures

    This press release contains the non-GAAP financial measures Adjusted EBITDA and Adjusted diluted EPS. Adjusted EBITDA is a Non-GAAP financial measure of earnings before interest, taxes, depreciation, and amortization that also excludes certain adjustments as indicated below in the reconciliation from net earnings. Adjusted diluted EPS is a Non-GAAP financial measure of diluted earnings per share that excludes certain adjustments as indicated below in the reconciliation from diluted EPS.

    Adjusted EBITDA (non-GAAP) is net earnings (loss) (its most directly comparable GAAP financial measure) adjusted for interest expense, net, (benefit from) provision for income taxes, depreciation and amortization, non-cash share-based compensation, and transaction-related expenses and integration costs for the Hiya acquisition. Adjusted EBITDA attributable to USANA (non-GAAP) is Adjusted EBITDA (non-GAAP) further adjusted to exclude the Adjusted EBITDA attributable to non-controlling interest related to Hiya.

    Adjusted diluted earnings per share (non-GAAP) is diluted earnings (loss) per share (its most directly comparable GAAP financial measure) adjusted for amortization of intangible assets, transaction-related expenses, and integration costs related to the Hiya acquisition.

    Management believes that Adjusted EBITDA (non-GAAP), Adjusted EBITDA attributable to USANA (non-GAAP), and Adjusted diluted earnings per share (non-GAAP), along with GAAP measures used by management, most appropriately reflect how the Company measures the business internally.

    The Company prepares its financial statements using U.S. generally accepted accounting principles ("GAAP") and investors should not directly compare with or infer relationship from any of the Company's operating results presented in accordance with GAAP to Adjusted EBITDA and Adjusted diluted earnings per share. Non-GAAP financial measures have limitations in their usefulness to investors because they have no standardized meaning prescribed by GAAP and are not prepared under any comprehensive set of accounting rules or principles. In addition, other companies, including companies in our industry, may calculate similarly titled non-GAAP financial measures differently or may use other measures to evaluate their performance, all of which could reduce the usefulness of non-GAAP financial information as a tool for comparison. As a result, the non-GAAP financial information of Hiya is presented for supplemental informational purposes only and should not be considered in isolation from, or as a substitute for financial information presented in accordance with GAAP.

    Reconciliation of Diluted Earnings Per Share (GAAP) to Adjusted Diluted Earnings Per Share (non-GAAP)

     

     

    Three

    Months

    Ended

     

    Three Months Ended

     

    Twelve Months Ended

     

    September

    28, 2024

     

    December

    28, 2024

     

    December

    30, 2023

     

    December

    28, 2024

     

    December

    30, 2023

    Net earnings attributable to USANA (GAAP)

    $

    10,607

     

    $

    4,454

     

     

    $

    16,766

     

    $

    42,030

     

     

    $

    63,788

     

     

     

     

     

     

     

     

     

     

    Earnings per common share - Diluted (GAAP)

    $

    0.56

     

    $

    0.23

     

     

    $

    0.87

     

    $

    2.19

     

     

    $

    3.30

    Weighted Average common shares outstanding - Diluted

     

    19,083

     

     

    19,104

     

     

     

    19,253

     

     

    19,162

     

     

     

    19,345

     

     

     

     

     

     

     

     

     

     

    Adjustment to net earnings:

     

     

     

     

     

     

     

     

     

    Transaction costs - Hiya

    $

    -

     

    $

    8,243

     

     

    $

    -

     

    $

    8,243

     

     

    $

    -

    Integration and transition costs - Hiya

     

    -

     

     

    -

     

     

     

    -

     

     

    -

     

     

     

    -

    Inventory step-up - Hiya

     

    -

     

     

    38

     

     

     

    -

     

     

    38

     

     

     

    -

    Amortization of intangible assets - Hiya

     

    -

     

     

    294

     

     

     

    -

     

     

    294

     

     

     

    -

    Adjustments to net earnings attributable to non-controlling interest

     

    -

     

     

    (70

    )

     

     

    -

     

     

    (70

    )

     

     

    -

    Income tax effect of adjustments to net earnings

     

    -

     

     

    (823

    )

     

     

    -

     

     

    (823

    )

     

     

    -

     

     

     

     

     

     

     

     

     

     

    Adjusted net earnings attributable to USANA

    $

    10,607

     

    $

    12,136

     

     

    $

    16,766

     

    $

    49,712

     

     

    $

    63,788

     

     

     

     

     

     

     

     

     

     

    Adjusted earnings per common share - Diluted

    $

    0.56

     

    $

    0.64

     

     

    $

    0.87

     

    $

    2.59

     

     

    $

    3.30

    Weighted average common shares outstanding - Diluted

     

    19,083

     

     

    19,104

     

     

     

    19,253

     

     

    19,162

     

     

     

    19,345

    Reconciliation of Net Earnings (GAAP) to Adjusted EBITDA (non-GAAP)

     

     

    Three

    Months

    Ended

     

    Three Months Ended

     

    Twelve Months Ended

     

    September

    28, 2024

     

    December

    28, 2024

     

    December

    30, 2023

     

    December

    28, 2024

     

    December

    30, 2023

    Net earnings attributable to USANA (GAAP)

    $

    10,607

     

     

    $

    4,454

     

     

    $

    16,766

     

     

    $

    42,030

     

     

    $

    63,788

     

    Net earnings attributable to non-controlling interest

     

    -

     

     

     

    30

     

     

     

    -

     

     

     

    30

     

     

     

    -

     

    Net earnings

    $

    10,607

     

     

    $

    4,484

     

     

    $

    16,766

     

     

    $

    42,060

     

     

    $

    63,788

     

     

     

     

     

     

     

     

     

     

     

    Adjustments:

     

     

     

     

     

     

     

     

     

    Income taxes

     

    8,001

     

     

     

    5,945

     

     

     

    9,845

     

     

     

    34,291

     

     

     

    38,665

     

    Interest (income) expense

     

    (3,093

    )

     

     

    (2,609

    )

     

     

    (2,760

    )

     

     

    (11,038

    )

     

     

    (9,375

    )

    Depreciation and amortization

     

    5,559

     

     

     

    5,590

     

     

     

    4,871

     

     

     

    21,935

     

     

     

    20,395

     

    Amortization of intangible assets - Hiya

     

    -

     

     

     

    294

     

     

     

    -

     

     

     

    294

     

     

     

    -

     

    Earnings before interest, taxes, depreciation, and amortization (EBITDA)

     

    21,074

     

     

     

    13,704

     

     

     

    28,722

     

     

     

    87,542

     

     

     

    113,473

     

     

     

     

     

     

     

     

     

     

     

    Add EBITDA adjustments:

     

     

     

     

     

     

     

     

     

    Non-cash share-based compensation

     

    3,542

     

     

     

    3,613

     

     

     

    3,643

     

     

     

    14,558

     

     

     

    14,595

     

    Transaction costs - Hiya

     

    -

     

     

     

    8,243

     

     

     

    -

     

     

     

    8,243

     

     

     

    -

     

    Integration and transition costs - Hiya

     

    -

     

     

     

    -

     

     

     

    -

     

     

     

    -

     

     

     

    -

     

    Inventory step-up - Hiya

     

    -

     

     

     

    38

     

     

     

    -

     

     

     

    38

     

     

     

    -

     

    Consolidated adjusted EBITDA

     

    24,616

     

     

     

    25,598

     

     

     

    32,365

     

     

     

    110,381

     

     

     

    128,068

     

    Less: Adjusted EBITDA attributable to non-controlling interest

     

    -

     

     

     

    (101

    )

     

     

    -

     

     

     

    (101

    )

     

     

    -

     

    Adjusted EBITDA attributable to USANA

    $

    24,616

     

     

    $

    25,497

     

     

    $

    32,365

     

     

    $

    110,280

     

     

    $

    128,068

     

    Management Commentary Document and Conference Call

    For further information on the USANA's operating results, please see the Management Commentary document, which has been posted on the Company's website (http://ir.usana.com) under the Investor Relations section. USANA's management team will hold a conference call and webcast to discuss today's announcement with investors on Wednesday, February 26, 2025 at 11:00 AM Eastern Time. Investors may listen to the call by accessing USANA's website at http://ir.usana.com. The call will consist of brief opening remarks by the Company's management team, followed by a questions and answers session.

    Safe Harbor

    This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. These forward-looking statements are based on current plans, expectations, estimates, forecasts, and projections as well as the beliefs and assumptions of management. Words such as "expect," "enhance," "drive," "anticipate," "intend," "improve," "promote," "should," "believe," "continue," "plan," "goal," "opportunity," "estimate," "predict," "may," "will," "could," and "would," and variations of these terms or the negative of these terms and similar expressions are intended to identify these forward-looking statements. Such forward-looking statements include, but are not limited to, statements that Hiya is a growing, highly cash-generative brand that is positioned to deliver long-term sustainable growth over the next several years and strong growth in 2025; statements about the Company's long-term growth; and the statements under the sub-heading "Fiscal Year 2025 Outlook." Our actual results could differ materially from those projected in these forward-looking statements, which involve a number of risks and uncertainties, many of which involve factors or circumstances that are beyond our control, including: risks relating to global economic conditions generally, including continued inflationary pressure around the world and negative impact on our operating costs, consumer demand and consumer behavior in general; reliance upon our network of independent Associates; risk that our Associate compensation plan, or changes that we make to the compensation plan, will not produce desired results, benefit our business or, in some cases, could harm our business; risk associated with our launch of new products or reformulated existing products; risks related to governmental regulation of our products, manufacturing and direct selling business model in the United States, China and other key markets; potential negative effects of deteriorating foreign and/or trade relations between or among the United States, China and other key markets, including potential adverse impact from tariffs levied by the US, China, or other markets that are important to the Company; potential negative effects from geopolitical relations and conflicts around the world, including the Russia-Ukraine conflict and the conflict in Israel; compliance with data privacy and security laws and regulations in our markets around the world; potential negative effects of material breaches of our information technology systems to the extent we experience a material breach; material failures of our information technology systems; adverse publicity risks globally; risks associated with early stage operations in India and future international expansion and operations; uncertainty relating to the fluctuation in U.S. and other international currencies; the potential for a resurgence of COVID-19, or another pandemic, in any of our markets in the future and any related impact on consumer health, domestic and world economies, including any negative impact on discretionary spending, consumer demand, and consumer behavior in general; risk that the Hiya acquisition disrupts each company's current plans and operations; the diversion of the attention of the management teams of USANA and Hiya from ongoing business operations; the ability of to retain key personnel of Hiya; the ability to realize the benefits of the acquisition, including efficiencies and cost synergies; the ability to successfully integrate Hiya's business with USANA's business, at all or in a timely manner; and the amount of the costs, fees, expenses and charges related to the acquisition. The contents of this release should be considered in conjunction with the risk factors, warnings, and cautionary statements that are contained in our most recent filings with the Securities and Exchange Commission. The forward-looking statements in this press release set forth our beliefs as of the date hereof. We do not undertake any obligation to update any forward-looking statement after the date hereof or to conform such statements to actual results or changes in the Company's expectations, except as required by law.

    About USANA

    USANA develops and manufactures high-quality nutritional supplements, functional foods and personal care products that are sold directly to Associates and Preferred Customers throughout the United States, Canada, Australia, New Zealand, Hong Kong, China, Japan, Taiwan, South Korea, Singapore, Mexico, Malaysia, the Philippines, the Netherlands, the United Kingdom, Thailand, France, Belgium, Colombia, Indonesia, Germany, Spain, Romania, Italy, and India. More information on USANA can be found at www.usana.com. USANA also holds a 78.8% controlling ownership stake in Hiya Health Products, a children's health and wellness company with a variety of clean-label products. More information on Hiya can be found at www.hiyahealth.com.

    USANA Health Sciences, Inc.
    Consolidated Statements of Operations
    (In thousands, except per share data)
    (Unaudited)
     
    Quarter Ended Twelve Months Ended
    28-Dec-24 30-Dec-23 28-Dec-24 30-Dec-23
     
    Net sales

    $

    213,613

     

    $

    221,083

    $

    854,503

     

    $

    921,010

    Cost of sales

     

    38,553

     

     

    42,319

     

    161,212

     

     

    176,693

    Gross profit

     

    175,060

     

     

    178,764

     

    693,291

     

     

    744,317

    Operating expenses:
    Associate incentives

     

    93,502

     

     

    95,881

     

    363,699

     

     

    394,257

    Selling, general and administrative

     

    73,348

     

     

    58,664

     

    263,268

     

     

    256,989

    Earnings from operations

     

    8,210

     

     

    24,219

     

    66,324

     

     

    93,071

    Other income (expense), net

     

    2,219

     

     

    2,392

     

    10,027

     

     

    9,382

    Earnings before income taxes

     

    10,429

     

     

    26,611

     

    76,351

     

     

    102,453

    Income taxes

     

    5,945

     

     

    9,845

     

    34,291

     

     

    38,665

    Net earnings

    $

    4,484

     

    $

    16,766

    $

    42,060

     

    $

    63,788

     
    Less (net earnings) loss attributable to non-controlling interest

     

    (30

    )

     

    -

     

    (30

    )

     

    -

    Net earnings attributable to USANA

    $

    4,454

     

    $

    16,766

    $

    42,030

     

    $

    63,788

     
    Earnings per share - diluted

    $

    0.23

     

    $

    0.87

    $

    2.19

     

    $

    3.30

    Weighted average shares outstanding - diluted

     

    19,104

     

     

    19,253

     

    19,162

     

     

    19,345

    USANA Health Sciences, Inc.
    Consolidated Balance Sheets
    (In thousands)
    (Unaudited)
     
    As of As of
    28-Dec-24 30-Dec-23
    ASSETS
    Current Assets
    Cash and cash equivalents

    $

    181,768

    $

    330,420

    Inventories

     

    69,735

     

    61,454

    Prepaid expenses and other current assets

     

    27,684

     

    25,872

    Total current assets

     

    279,187

     

    417,746

     
    Property and equipment, net

     

    94,565

     

    99,814

     
    Goodwill

     

    144,168

     

    17,102

    Intangible assets, net

     

    151,823

     

    29,919

    Deferred tax assets

     

    19,644

     

    13,284

    Other assets*

     

    58,806

     

    54,892

    Total assets

    $

    748,193

    $

    632,757

     
    LIABILITIES AND STOCKHOLDERS' EQUITY
    Current Liabilities
    Accounts payable

    $

    11,984

    $

    10,070

    Line of credit - short term

     

    23,000

     

    786

    Other current liabilities

     

    104,641

     

    107,989

    Total current liabilities

     

    139,625

     

    118,845

     
    Deferred tax liabilities

     

    4,073

     

    4,552

    Other long-term liabilities

     

    18,163

     

    12,158

     
    Non-controlling interest

     

    54,223

     

    -

     
    Stockholders' equity

     

    532,109

     

    497,202

    Total liabilities and stockholders' equity

    $

    748,193

    $

    632,757

    *Includes noncurrent inventories of $2,688 and $3,128 as of 28-Dec-24 and 30-Dec-23, respectively. Total inventories were $72,423 and $64,582 as of 28-Dec-24 and 30-Dec-23, respectively.
     
    USANA Health Sciences, Inc.
    Sales by Region
    (In thousands)
    (Unaudited)
     
    Quarter Ended
    December 28, 2024 December 30, 2023 Change from prior year Currency

    impact on

    sales
    % change

    excluding

    currency

    impact
    Asia Pacific
    Greater China

    $

    112,587

    52.7

    %

    $

    115,921

    52.4

    %

    $

    (3,334

    )

    (2.9

    %)

    $

    353

     

    (3.2

    %)

    Southeast Asia Pacific

     

    38,061

    17.8

    %

     

    39,116

    17.7

    %

     

    (1,055

    )

    (2.7

    %)

     

    562

     

    (4.1

    %)

    North Asia

     

    16,542

    7.8

    %

     

    22,065

    10.0

    %

     

    (5,523

    )

    (25.0

    %)

     

    (883

    )

    (21.0

    %)

    Asia Pacific Total

     

    167,190

    78.3

    %

     

    177,102

    80.1

    %

     

    (9,912

    )

    (5.6

    %)

     

    32

     

    (5.6

    %)

     
    Americas and Europe

     

    44,453

    20.8

    %

     

    43,981

    19.9

    %

     

    472

     

    1.1

    %

     

    (1,061

    )

    3.5

    %

    Total USANA

     

    211,643

    99.1

    %

     

    221,083

    100.0

    %

     

    (9,440

    )

    (4.3

    %)

     

    (1,029

    )

    (3.8

    %)

     
    Hiya

     

    1,970

    0.9

    %

     

    1,970

     

     

    -

     

    Consolidated Total

    $

    213,613

    100.0

    %

    $

    221,083

    100.0

    %

    $

    (7,470

    )

    (3.4

    %)

    $

    (1,029

    )

    (2.9

    %)

    USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES

    ACTIVE ASSOCIATES AND ACTIVE PREFERRED CUSTOMERS BY REGION

    (unaudited)

     
    Active Associates by Region(1)
    (Unaudited)
     
    As of
    December 28, 2024 December 30, 2023
    Asia Pacific
    Greater China

    67,000

    35.4

    %

    70,000

    35.0

    %

    Southeast Asia Pacific

    51,000

    27.0

    %

    52,000

    26.0

    %

    North Asia

    26,000

    13.8

    %

    32,000

    16.0

    %

    Asia Pacific Total

    144,000

    76.2

    %

    154,000

    77.0

    %

     
    Americas and Europe

    45,000

    23.8

    %

    46,000

    23.0

    %

    189,000

    100.0

    %

    200,000

    100.0

    %

     
     
    Active Preferred Customers by Region (2)
    (Unaudited)
     
    As of
    December 28, 2024 December 30, 2023
    Asia Pacific
    Greater China

    179,000

    67.6

    %

    185,000

    65.4

    %

    Southeast Asia Pacific

    26,000

    9.8

    %

    28,000

    9.9

    %

    North Asia

    12,000

    4.5

    %

    16,000

    5.6

    %

    Asia Pacific Total

    217,000

    81.9

    %

    229,000

    80.9

    %

     
    Americas and Europe

    48,000

    18.1

    %

    54,000

    19.1

    %

    265,000

    100.0

    %

    283,000

    100.0

    %

    (1) Associates are independent distributors of our products who also purchase our products for their personal use. We only count as active those Associates who have purchased from us any time during the most recent three-month period, either for personal use or resale.

    (2) Preferred Customers purchase our products strictly for their personal use and are not permitted to resell or to distribute the products. We only count as active those Preferred Customers who have purchased from us any time during the most recent three-month period. China utilizes a Preferred Customer program that has been implemented specifically for that market.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250225808997/en/

    Investor contact:

    Andrew Masuda

    Investor Relations

    (801) 954-7201

    [email protected]

    Media contact:

    Sarah Searle

    (801) 954-7626

    [email protected]

    Get the next $USNA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $USNA

    DatePrice TargetRatingAnalyst
    6/23/2023Buy
    Sidoti
    7/7/2022$78.00 → $53.00Hold → Underperform
    Jefferies
    4/14/2022$86.00Neutral
    DA Davidson
    More analyst ratings

    $USNA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Sidoti initiated coverage on USANA

      Sidoti initiated coverage of USANA with a rating of Buy

      6/23/23 9:12:38 AM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care
    • USANA downgraded by Jefferies with a new price target

      Jefferies downgraded USANA from Hold to Underperform and set a new price target of $53.00 from $78.00 previously

      7/7/22 9:35:48 AM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care
    • DA Davidson initiated coverage on USANA with a new price target

      DA Davidson initiated coverage of USANA with a rating of Neutral and set a new price target of $86.00

      4/14/22 7:45:27 AM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care

    $USNA
    Financials

    Live finance-specific insights

    See more
    • USANA Health Sciences Reports First Quarter 2025 Results and Reiterates Full-Year Outlook

      USANA Health Sciences, Inc. (NYSE:USNA) today announced financial results for its fiscal first quarter ended March 29, 2025. Key Financial Results First Quarter 2025 vs. First Quarter 2024 Net sales of $250 million versus $228 million, representing year-over-year growth of 10% and 12% in constant currency. Net earnings of $9.4 million versus $16.5 million. Diluted EPS of $0.49 as compared with $0.86. Adjusted diluted EPS(1) of $0.73 as compared with $0.86. Adjusted EBITDA(2) of $30 million versus $33 million. Direct selling Active Customers of 459,000 versus 494,000. Hiya Active Monthly Subscribers of 224,000. Company reiterates fiscal year 2025 outlook. Q1 2025 Financia

      4/22/25 4:05:00 PM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care
    • USANA Schedules First Quarter 2025 Earnings Release and Conference Call

      USANA Health Sciences, Inc. (NYSE:USNA) today announced that first quarter 2025 results will be released after the close of market on Tuesday, April 22, 2025. Shortly following the issuance of the Company's earnings release, the Company will post its Management Commentary document on the Company's Investor Relations website (http://ir.usana.com) under the News/Events section. USANA will hold a conference call to discuss this announcement with analysts and institutional investors the following morning, Wednesday, April 23, 2025 at 11:00 a.m. Eastern Time. The call will be broadcast over the Internet and can be accessed at http://ir.usana.com. About USANA USANA develops and manufactures hi

      4/8/25 4:05:00 PM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care
    • USANA Health Sciences Reports Fourth Quarter and Full Year 2024 Results and Provides Fiscal Year 2025 Outlook

      USANA Health Sciences, Inc. (NYSE:USNA) (the "Company") today announced financial results for its fiscal fourth quarter and fiscal year ended December 28, 2024. The Company completed the acquisition of a 78.8% controlling ownership stake of Hiya Health Products, LLC ("Hiya") on December 23, 2024. Consequently, the Company's fourth quarter and fiscal year 2024 include the effect of less than a week of Hiya's operating results, which were not significant to the Company's consolidated results for the same periods. In light of the Hiya acquisition, the Company is now including metrics for Adjusted diluted EPS(1) and Adjusted EBITDA(2). Net earnings, Diluted EPS, Adjusted diluted EPS(1) and Adju

      2/25/25 4:10:00 PM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care

    $USNA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • USANA Releases 2024 Sustainability Report

      Highlighting USANA's ongoing commitment to people, planet, and products SALT LAKE CITY, May 8, 2025 /PRNewswire/ -- As a global leader in health and wellness, USANA is dedicated to doing its part in creating a better, healthier world. And with a commitment to positive business practices, USANA recently released its fifth annual sustainability report. This review of USANA's 2024 sustainability efforts and progress includes organizational priorities based on a comprehensive stakeholder assessment. To view the full 2024 sustainability report, please click here. "In unveiling our

      5/8/25 8:56:00 AM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care
    • Kevin Guest Shares Transformative Success Strategies on Executive Coaching Day, May 1

      SALT LAKE CITY, May 1, 2025 /PRNewswire/ -- Kevin Guest, Executive Chairman at USANA Health Sciences (NYSE:USNA) and acclaimed author of All the Right Reasons, 12 Timeless Principles for Living a Life in Harmony, is sharing valuable insights for professionals striving to reach their peak potential. As part of Executive Coaching Day on May 1, Guest is combining decades of leadership experience with principles outlined in his bestselling book to offer actionable steps for success both in the boardroom and in life. "True success isn't just about achieving your goals; it's about l

      5/1/25 7:47:00 AM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care
    • USANA Celavive Postbiotic Rescue Serum Selected as a Good Housekeeping 2025 Beauty Award Winner

      SALT LAKE CITY, April 28, 2025 /PRNewswire/ -- USANA Health Sciences, Inc., a global leader in cellular nutrition, announced today that its Celavive Postbiotic Rescue Serum was named as a winner in Good Housekeeping's 2025 Beauty Awards. The full list of awards can be found here. To learn more about USANA and the science behind its products, please visit USANA.com. "We're so excited that our Postbiotic Rescue Serum has been named a Good Housekeeping 2025 Beauty Award winner," said Brent Neidig, USANA's chief commercial officer. "Our product and R&D teams have put so much time

      4/28/25 7:27:00 AM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care

    $USNA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by USANA Health Sciences Inc. (Amendment)

      SC 13G/A - USANA HEALTH SCIENCES INC (0000896264) (Subject)

      2/13/24 10:49:58 AM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by USANA Health Sciences Inc. (Amendment)

      SC 13G/A - USANA HEALTH SCIENCES INC (0000896264) (Subject)

      2/13/23 11:26:45 AM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by USANA Health Sciences Inc. (Amendment)

      SC 13G/A - USANA HEALTH SCIENCES INC (0000896264) (Subject)

      2/11/22 3:48:24 PM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care

    $USNA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CHIEF FINANCIAL OFFICER Iiekking G Doug sold $134,662 worth of shares (4,548 units at $29.61), closing all direct ownership in the company (SEC Form 4)

      4 - USANA HEALTH SCIENCES INC (0000896264) (Issuer)

      5/12/25 10:42:33 AM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care
    • Director Wood Timothy E converted options into 674 shares and covered exercise/tax liability with 169 shares, increasing direct ownership by 7% to 7,442 units (SEC Form 4)

      4 - USANA HEALTH SCIENCES INC (0000896264) (Issuer)

      5/6/25 4:02:48 PM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care
    • Director Winssinger Frederic J converted options into 674 shares, increasing direct ownership by 13% to 5,871 units (SEC Form 4)

      4 - USANA HEALTH SCIENCES INC (0000896264) (Issuer)

      5/6/25 4:01:06 PM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care

    $USNA
    Leadership Updates

    Live Leadership Updates

    See more
    • USANA Exec. Chairman Kevin Guest Celebrates Guitar Month, Stress Awareness Month for Harmony

      SALT LAKE CITY, April 1, 2025 /PRNewswire/ -- USANA Health Sciences (NYSE:USNA) Executive Chairman Kevin Guest marks April's convergence of International Guitar Month and Stress Awareness Month, as a perfect pairing that celebrates the healing power of music for mental well-being. While music has long been heralded as a universal remedy, the guitar offers far more than just melodies. Studies, stories and specialists alike agree: playing the guitar is a proven method to reduce stress. A passionate, performing guitarist himself, Guest invites others to join the cause. "Music has

      4/1/25 7:47:00 AM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care
    • USANA Appoints New Chief Scientific Officer

      Dr. Kathryn Armstrong brings 17 years of scientific expertise to the company SALT LAKE CITY, Jan. 22, 2025 /PRNewswire/ -- USANA Health Sciences, Inc., a global leader in cellular nutrition, is proud to announce that Dr. Kathryn Armstrong, Ph.D., will be assuming the role of chief scientific officer at the company. Kathryn has served as USANA's executive vice president of research and development since July of 2024.  Kathryn's predecessor, Dr. Rob Sinnott, announced his retirement at the end of 2024, but will continue to assist in the company's pursuit for scientific excellence as its senior scientific fellow.

      1/22/25 7:07:00 AM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care
    • USANA Executive Chairman Kevin Guest Encourages Connections with July's "Social Wellness Month"

      SALT LAKE CITY, July 1, 2024 /PRNewswire/ -- Throughout July, Kevin Guest, executive chairman at USANA Health Sciences (NYSE:USNA), is emphasizing boosting social connections during "Social Wellness Month." Social wellness—the ability to form meaningful relationships and interact positively with others—not only enhances our emotional well-being but also significantly impacts our overall health. "Strong social connections reduce stress, improve mental health, and even extend life expectancy," said Guest. "In a world where digital interactions often replace face-to-face communic

      7/1/24 7:13:00 AM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care

    $USNA
    SEC Filings

    See more
    • SEC Form 10-Q filed by USANA Health Sciences Inc.

      10-Q - USANA HEALTH SCIENCES INC (0000896264) (Filer)

      5/6/25 2:42:26 PM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form DEFA14A filed by USANA Health Sciences Inc.

      DEFA14A - USANA HEALTH SCIENCES INC (0000896264) (Filer)

      5/1/25 4:44:16 PM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by USANA Health Sciences Inc.

      SCHEDULE 13G/A - USANA HEALTH SCIENCES INC (0000896264) (Subject)

      4/30/25 11:13:38 AM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care